Hanson, professor of laboratory medicine and pathology, Mayo Clinic College of Medicine, explained the structure and function of IGHV, the mutation assay, and the clinical value of …

Hypermutation status provides prognostic information for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Hypermutation (mutated) is defined …

Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement

immunoglobulin heavy chain variable region (IGHV) gene in clonal B cell populations. CLL patients with non-mutated IGHV genes have a poorer clinical prognosis. In addition, cases of …

In addition, immunoglobulin heavy chain variable region (IGHV) gene hypermutation status provides important prognostic information for patients with chronic lymphocytic leukemia (CLL) …

The somatic hypermutation status of the immunoglobulin heavy variable (IGHV) gene is a biomarker for assessing the prognosis of patients with chronic lymphocytic leukemia (CLL) and …

Somatic hypermutation status of the IGHV gene is essential for treating patients with chronic lym-phocytic leukemia/small lymphocytic lymphoma. Unlike the conventional low-throughput …

Oct 16, 2024 · Patients with unmutated immunoglobulin heavy chain variable (IGHV) status exhibit a more aggressive disease course, poorer outcomes, and reduced response to …

Magdalena Zawada et al., IGHV mutations assay methodology and reporting principles a better prognosis. The IGHV mutation status indicates the stage of B lymphocyte differentiation at …

In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic …